ESMO at 40: thoughts on medical oncology
This article was originally published in Scrip
The European Society of Medical Oncology's congress at the end of September launched a year of quadragennial celebration. More than 18,000 people converged on Madrid for the event, something that was probably beyond the dreams of the organizers of the inaugural conference in Nice in 1975, when 100 people attended and the mission statement included working "on full recognition of medical oncology in Europe".
You may also be interested in...
GlamorousAI is developing technology to uncover new targets and take on previously intractable disease challenges. Founder Noor Shaker hopes to license a drug to big pharma within the next three years.
INFOGRAPHIC: In 2019, 10 blockbuster medicines booked combined sales of $92.5bn. This infographic examines those drugs that commanded the greatest revenues globally, and answers some key questions. Which therapeutic areas include the most lucrative blockbusters? Which companies enjoyed their spoils? And which drugs were new to the top 10 last year? It also takes a look at the position of these products on the all-important US market.
Fundraising in the life sciences sector has been booming even as firms in many other industries are struggling to stay in business. Goodwin’s David Mardle is upbeat about the sector’s ongoing prospects – although M&A deals are currently proving tricky to complete.